O	0	9	Molecular	Molecular	JJ	B-NP
O	10	17	biology	biology	NN	I-NP
O	18	20	of	of	IN	B-PP
B-Cancer	21	29	cervical	cervical	JJ	B-NP
I-Cancer	30	36	cancer	cancer	NN	I-NP
O	37	40	and	and	CC	O
O	41	44	its	its	PRP$	B-NP
B-Pathological_formation	45	55	precursors	precursor	NNS	I-NP
O	55	56	.	.	.	O

B-Cancer	58	66	Cervical	Cervical	JJ	B-NP
I-Cancer	67	73	cancer	cancer	NN	I-NP
O	74	82	develops	develop	VBZ	B-VP
O	83	87	from	from	IN	B-PP
O	88	92	well	well	RB	B-NP
O	92	93	-	-	HYPH	I-NP
O	93	100	defined	define	VBN	I-NP
B-Pathological_formation	101	110	precursor	precursor	NN	I-NP
I-Pathological_formation	111	118	lesions	lesion	NNS	I-NP
O	119	127	referred	refer	VBN	B-VP
O	128	130	to	to	TO	B-PP
O	131	133	as	as	IN	B-PP
O	134	140	either	either	CC	B-NP
B-Pathological_formation	141	149	cervical	cervical	JJ	I-NP
I-Pathological_formation	150	165	intraepithelial	intraepithelial	JJ	I-NP
I-Pathological_formation	166	175	neoplasia	neoplasia	NN	I-NP
O	176	178	or	or	CC	O
B-Pathological_formation	179	187	squamous	squamous	JJ	B-NP
I-Pathological_formation	188	203	intraepithelial	intraepithelial	JJ	I-NP
I-Pathological_formation	204	211	lesions	lesion	NNS	I-NP
O	211	212	.	.	.	O

O	213	215	It	It	PRP	B-NP
O	216	218	is	be	VBZ	B-VP
O	219	222	now	now	RB	I-VP
O	223	228	known	know	VBN	I-VP
O	229	233	that	that	IN	B-SBAR
O	234	242	specific	specific	JJ	B-NP
O	243	248	types	type	NNS	I-NP
O	249	251	of	of	IN	B-PP
O	252	257	human	human	JJ	B-NP
O	258	274	papillomaviruses	papillomavirus	NNS	I-NP
O	275	276	(	(	(	O
O	276	279	HPV	HPV	NN	B-NP
O	279	280	)	)	)	O
O	281	284	are	be	VBP	B-VP
O	285	288	the	the	DT	B-NP
O	289	298	principal	principal	JJ	I-NP
O	299	308	etiologic	etiologic	JJ	I-NP
O	309	315	agents	agent	NNS	I-NP
O	316	319	for	for	IN	B-PP
O	320	324	both	both	CC	B-NP
B-Cancer	325	333	cervical	cervical	JJ	I-NP
I-Cancer	334	340	cancer	cancer	NN	I-NP
O	341	344	and	and	CC	O
O	345	348	its	its	PRP$	B-NP
B-Pathological_formation	349	359	precursors	precursor	NNS	I-NP
O	359	360	.	.	.	O

O	361	364	The	The	DT	B-NP
O	365	369	high	high	JJ	I-NP
O	369	370	-	-	HYPH	I-NP
O	370	379	oncogenic	oncogenic	JJ	I-NP
O	379	380	-	-	HYPH	I-NP
O	380	384	risk	risk	NN	I-NP
O	385	388	HPV	HPV	NN	I-NP
O	389	394	types	type	NNS	I-NP
O	395	405	associated	associate	VBN	B-VP
O	406	410	with	with	IN	B-PP
B-Cancer	411	419	invasive	invasive	JJ	B-NP
I-Cancer	420	428	cervical	cervical	JJ	I-NP
I-Cancer	429	435	cancer	cancer	NN	I-NP
O	436	443	produce	produce	VBP	B-VP
O	444	447	two	two	CD	B-NP
O	448	460	oncoproteins	oncoprotein	NNS	I-NP
O	460	461	,	,	,	O
O	462	472	designated	designate	VBN	B-NP
O	473	475	E6	E6	NN	I-NP
O	476	479	and	and	CC	I-NP
O	480	482	E7	E7	NN	I-NP
O	482	483	,	,	,	O
O	484	489	which	which	WDT	B-NP
O	490	498	interact	interact	VBP	B-VP
O	499	503	with	with	IN	B-PP
O	504	514	endogenous	endogenous	JJ	B-NP
B-Cell	515	519	cell	cell	NN	I-NP
O	520	525	cycle	cycle	NN	I-NP
O	526	536	regulatory	regulatory	JJ	I-NP
O	537	545	proteins	protein	NNS	I-NP
O	545	546	,	,	,	O
O	547	556	including	include	VBG	B-PP
O	557	560	p53	p53	NN	B-NP
O	561	564	and	and	CC	I-NP
O	565	567	Rb	Rb	NN	I-NP
O	567	568	.	.	.	O

O	569	572	The	The	DT	B-NP
O	573	584	interaction	interaction	NN	I-NP
O	585	587	of	of	IN	B-PP
O	588	595	virally	virally	RB	B-NP
O	596	603	derived	derive	VBN	I-NP
O	604	607	and	and	CC	I-NP
O	608	618	endogenous	endogenous	JJ	I-NP
B-Cell	619	627	cellular	cellular	JJ	I-NP
O	628	636	proteins	protein	NNS	I-NP
O	637	646	converges	converge	VBZ	B-VP
O	647	649	in	in	IN	B-PP
O	650	662	deregulation	deregulation	NN	B-NP
O	663	665	of	of	IN	B-PP
B-Cell	666	670	cell	cell	NN	B-NP
O	671	676	cycle	cycle	NN	I-NP
O	677	688	progression	progression	NN	I-NP
O	689	692	and	and	CC	O
O	693	700	appears	appear	VBZ	B-VP
O	701	703	to	to	TO	I-VP
O	704	706	be	be	VB	I-VP
O	707	715	critical	critical	JJ	B-ADJP
O	716	719	for	for	IN	B-PP
O	720	723	the	the	DT	B-NP
O	724	735	development	development	NN	I-NP
O	736	738	of	of	IN	B-PP
B-Cancer	739	747	cervical	cervical	JJ	B-NP
I-Cancer	748	755	cancers	cancer	NNS	I-NP
O	755	756	.	.	.	O

O	757	764	However	However	RB	B-ADVP
O	764	765	,	,	,	O
O	766	769	the	the	DT	B-NP
O	770	781	development	development	NN	I-NP
O	782	784	of	of	IN	B-PP
B-Cancer	785	793	cervical	cervical	JJ	B-NP
I-Cancer	794	800	cancer	cancer	NN	I-NP
O	801	803	is	be	VBZ	B-VP
O	804	805	a	a	DT	B-NP
O	806	815	multistep	multistep	JJ	I-NP
O	816	823	process	process	NN	I-NP
O	824	828	that	that	WDT	B-NP
O	829	835	cannot	cannot	MD	B-VP
O	836	838	be	be	VB	I-VP
O	839	848	explained	explain	VBN	I-VP
O	849	855	simply	simply	RB	B-ADVP
O	856	858	by	by	IN	B-PP
O	859	868	infection	infection	NN	B-NP
O	869	873	with	with	IN	B-PP
O	874	882	specific	specific	JJ	B-NP
O	883	888	types	type	NNS	I-NP
O	889	891	of	of	IN	B-PP
O	892	895	HPV	HPV	NN	B-NP
O	895	896	.	.	.	O

O	897	900	One	One	CD	B-NP
O	901	911	additional	additional	JJ	I-NP
O	912	917	event	event	NN	I-NP
O	918	922	that	that	WDT	B-NP
O	923	930	appears	appear	VBZ	B-VP
O	931	933	to	to	TO	I-VP
O	934	938	play	play	VB	I-VP
O	939	940	a	a	DT	B-NP
O	941	945	role	role	NN	I-NP
O	946	948	in	in	IN	B-PP
B-Cancer	949	954	tumor	tumor	NN	B-NP
O	955	966	progression	progression	NN	I-NP
O	967	969	is	be	VBZ	B-VP
O	970	981	integration	integration	NN	B-NP
O	982	984	of	of	IN	B-PP
O	985	988	HPV	HPV	NN	B-NP
O	989	992	DNA	DNA	NN	I-NP
O	993	997	into	into	IN	B-PP
O	998	1001	the	the	DT	B-NP
O	1002	1006	host	host	NN	I-NP
O	1007	1013	genome	genome	NN	I-NP
O	1013	1014	.	.	.	O

O	1015	1026	Integration	Integration	NN	B-NP
O	1027	1029	of	of	IN	B-PP
O	1030	1033	HPV	HPV	NN	B-NP
O	1034	1037	DNA	DNA	NN	I-NP
O	1038	1048	frequently	frequently	RB	B-ADVP
O	1049	1057	disrupts	disrupt	VBZ	B-VP
O	1058	1061	the	the	DT	B-NP
O	1062	1064	E2	E2	NN	I-NP
O	1065	1069	open	open	JJ	I-NP
O	1070	1077	reading	reading	NN	I-NP
O	1078	1084	frames	frame	NNS	I-NP
O	1084	1085	,	,	,	O
O	1086	1095	resulting	result	VBG	B-VP
O	1096	1098	in	in	IN	B-PP
O	1099	1113	overexpression	overexpression	NN	B-NP
O	1114	1116	of	of	IN	B-PP
O	1117	1120	the	the	DT	B-NP
O	1121	1123	E6	E6	NN	I-NP
O	1124	1127	and	and	CC	I-NP
O	1128	1130	E7	E7	NN	I-NP
O	1131	1143	oncoproteins	oncoprotein	NNS	I-NP
O	1144	1147	and	and	CC	O
O	1148	1156	possibly	possibly	RB	B-VP
O	1157	1164	causing	cause	VBG	I-VP
O	1165	1172	genomic	genomic	JJ	B-NP
O	1173	1184	instability	instability	NN	I-NP
O	1184	1185	.	.	.	O

O	1186	1196	Additional	Additional	JJ	B-NP
O	1197	1206	cofactors	cofactor	NNS	I-NP
O	1207	1210	and	and	CC	O
O	1211	1221	mutational	mutational	JJ	B-NP
O	1222	1228	events	event	NNS	I-NP
O	1229	1232	may	may	MD	B-VP
O	1233	1235	be	be	VB	I-VP
O	1236	1245	important	important	JJ	B-ADJP
O	1246	1248	in	in	IN	B-PP
O	1249	1252	the	the	DT	B-NP
O	1253	1265	pathogenesis	pathogenesis	NN	I-NP
O	1266	1268	of	of	IN	B-PP
B-Cancer	1269	1277	invasive	invasive	JJ	B-NP
I-Cancer	1278	1286	cervical	cervical	JJ	I-NP
I-Cancer	1287	1294	cancers	cancer	NNS	I-NP
O	1295	1298	and	and	CC	O
O	1299	1302	may	may	MD	B-VP
O	1303	1310	include	include	VB	I-VP
B-Cellular_component	1311	1322	chromosomal	chromosomal	JJ	B-NP
O	1323	1337	rearrangements	rearrangement	NNS	I-NP
O	1337	1338	,	,	,	O
O	1339	1343	loss	loss	NN	B-NP
O	1344	1346	of	of	IN	B-PP
O	1347	1361	constitutional	constitutional	JJ	B-NP
O	1362	1376	heterozygosity	heterozygosity	NN	I-NP
O	1376	1377	,	,	,	O
O	1378	1381	and	and	CC	O
O	1382	1387	proto	proto	AFX	B-NP
O	1387	1388	-	-	HYPH	I-NP
O	1388	1396	oncogene	oncogene	NN	B-NP
O	1397	1407	activation	activation	NN	I-NP
O	1407	1408	.	.	.	O

